ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Directors Resign

<< Previous

Bullboard Posts

Next >>

Comment by BrokenPromison Nov 11, 2020 10:05am

96 Views

Post# 31876786

RE:RE:Directors Resign

I will throw my shares in for a vote. How many can we realistically gather? I have been following these threads for a few months and I hear a LOT of frustration and "in-house" fighting. I too am extremely frustrated with the stock performance. I am in for an excruciating $0.18 USD per share. I still think this could be a $10.00 stock if we get the right management team in place. It's time to stage a coup...

<< Previous

Bullboard Posts

Next >>

5 steps to mastering risk management in the stock market